Artivion Dirección

Dirección controles de criterios 3/4

El CEO de Artivion's es Pat Mackin , nombrado en Sep 2014, tiene una permanencia de 9.58 años. compensación anual total es $3.18M, compuesta por 24.4% salario y 75.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.6% de las acciones de la empresa, por valor de €12.99M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 7.5 años, respectivamente.

Información clave

Pat Mackin

Chief Executive Officer (CEO)

US$3.2m

Compensación total

Porcentaje del salario del CEO	24.4%
Permanencia del CEO	9.8yrs
Participación del CEO	1.6%
Permanencia media de la dirección	3.9yrs
Promedio de permanencia en la Junta Directiva	7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pat Mackin en comparación con los beneficios de Artivion?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$3m	US$776k	-US$31m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$7m	US$750k	-US$19m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$5m	US$728k	-US$15m
Sep 30 2021	n/a	n/a	US$2m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$3m	US$606k	-US$17m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$6m	US$689k	US$2m
Sep 30 2019	n/a	n/a	US$2m
Jun 30 2019	n/a	n/a	US$3m
Mar 31 2019	n/a	n/a	US$709k
Dec 31 2018	US$3m	US$660k	-US$3m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$3m	US$640k	US$4m

Compensación vs. Mercado: La compensación total de Pat($USD3.18M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.29M).

Compensación vs. Ingresos: La compensación de Pat ha sido consistente con los resultados de la empresa en el último año.

CEO

Pat Mackin (57 yo)

9.8yrs

Permanencia

US$3,176,413

Compensación

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Mackin	Chairman	9.8yrs	US$3.18m	1.6% $ 14.4m
Lance Berry	Executive VP of Finance	less than a year	US$1.64m	0.19% $ 1.7m
Amy Horton	VP & Chief Accounting Officer	17.8yrs	US$1.06m	0.33% $ 2.9m
Jean Holloway	Senior VP	9.2yrs	US$993.72k	0.40% $ 3.6m
John Davis	Senior VP & Chief Commercial Officer	less than a year	US$953.41k	0.38% $ 3.4m
Matthew Getz	VP of Human Resources & Chief Human Resources Officer	4.8yrs	sin datos	0.10% $ 940.8k
Marshall Stanton	Senior VP of Clinical Research & Chief Medical Officer	3.3yrs	US$1.61m	0.20% $ 1.8m
Robert Thomson	Vice President of Research & Development	less than a year	sin datos	0.032% $ 287.2k
Florian Tyrs	Vice President of Global Operations	3.9yrs	sin datos	0.062% $ 555.1k

3.9yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CYL se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Mackin	Chairman	9.7yrs	US$3.18m	1.6% $ 14.4m
James Bullock	Independent Director	7.7yrs	US$217.50k	0.15% $ 1.3m
Thomas Ackerman	Independent Director	20.5yrs	US$230.00k	0.34% $ 3.1m
Anthony Semedo	Independent Director	2.7yrs	US$217.50k	0.11% $ 947.9k
Daniel Bevevino	Independent Director	20.5yrs	US$235.00k	0.34% $ 3.1m
Jeffrey Burbank	Independent Presiding Director	6.8yrs	US$265.00k	0.11% $ 1.0m
Jon Salveson	Independent Director	12.1yrs	US$215.00k	0.30% $ 2.7m
Marna Borgstrom	Independent Director	6yrs	US$220.00k	0.10% $ 924.0k
Elizabeth Hoff	Independent Director	1.7yrs	US$210.00k	0.060% $ 541.6k

7.7yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de CYL se considera experimentada (7.5 años de antigüedad promedio).

Artivion Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Artivion, Inc., Annual General Meeting, May 14, 2024

Chairman recently sold €241k worth of stock

Chairman recently sold €224k worth of stock

Artivion, Inc. Announces Chief Financial Officer Changes

Senior Vice President of Operations recently sold €232k worth of stock

Chairman recently sold €276k worth of stock

Recent updates

Artivion, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.18 (vs US$0.33 loss in 1Q 2023)

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold €241k worth of stock

Full year 2023 earnings released: US$0.75 loss per share (vs US$0.48 loss in FY 2022)

Chairman recently sold €224k worth of stock

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$0.75 loss per share (vs US$0.48 loss in FY 2022)

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Artivion, Inc. Announces Chief Financial Officer Changes

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.34 loss in 3Q 2022)

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 2Q 2022)

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Senior Vice President of Operations recently sold €232k worth of stock

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.085 loss in 1Q 2022)

Chairman recently sold €276k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings released: US$0.48 loss per share (vs US$0.38 loss in FY 2021)

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Insider recently sold €122k worth of stock

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.056 loss in 2Q 2021)

Artivion, Inc. Provides Financial Guidance for the Year 2022

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Artivion, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.085 loss per share (vs US$0.08 loss in 1Q 2021)

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Insufficient new directors

Artivion, Inc. to Report Q1, 2022 Results on May 05, 2022

Artivion, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Artivion Provides Revenue Guidance for the Full Year 2022

Artivion, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Artivion, Inc. Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in the Annals of Thoracic Surgery

Insufficient new directors

Director recently bought €231k worth of stock

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.075 loss in 3Q 2020)

Insider recently sold €59k worth of stock

Insufficient new directors

Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.098 loss in 2Q 2020)

Insufficient new directors

CryoLife, Inc.(NYSE:CRY) dropped from Russell 2000 Value-Defensive Index

CryoLife, Inc.(NYSE:CRY) dropped from Russell 2000 Defensive Index

Cryolife, Inc. Not to Provide Full Year 2021 Financial Guidance

CryoLife, Inc. Announces Retirement of Michael S. Simpson as Senior Vice President, Regulatory Affairs and Quality Assurance

CryoLife, Inc. Is Not Issuing 2021 Financial Guidance

Revenue beats expectations

Full year 2020 earnings released: US$0.44 loss per share (vs US$0.046 profit in FY 2019)

New 90-day high: €21.20

CryoLife, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Cryolife, Inc. Not to Provide Earnings Guidance for the Year 2020

CryoLife, Inc. (NYSE:CRY) acquired Ascyrus Medical LLC from a group of shareholders for approximately $220 million.

Cryolife, Inc. Announces Not to Provide Financial Guidance

New 90-day low - €15.60